CROI 2026: 15 i-Base reports from this essential conference

24 April 2026. Related: Conference reports, CROI 33 (Retrovirus) 2026.

Simon Collins, HIV i-Base

This page lists all i-Base reports the recent CROI 2026 conference held in Denver from 22 to 25 February,

All reports include hyperlinks to abstracts, poster and webcasts.

• CROI 2026: investigational HIV combinations – daily, weekly, 4- and 6-monthly…
  Short review of exciting results and potential cautions with new ART combinations.
• CROI 2026: Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2
  Update on rare cases of breakthrough HIV infection using lenacapavir PrEP.
• CROI 2026: Second course of bNAbs slows viral rebound in RIO study and to lower levels
  The second stage of RIO study compared viral dynamics after a second course of bNAbs when viral load took longer to rebound and to lower peak levels after a second course of treatment.
• CROI 2026: GLP-1 weight loss drugs include potential immune benefits in gut tissue
  GLP-1 studies of weight loss drugs included short-term impact in a real world setting, potential benefits on reducing smoking, cardiovascular risk, depression, and liver fibrosis with the oral abstract on the potential to perhaps reverse the gut damage that occurs in very early HIV infection and that persists despite effective ART. Still lots of gaps in data though.
• CROI 2026: once-daily oral BIC/LEN simplifies ART for those on complex combinations
  A new once-daily pill can effectively simplify ART for many on complicated combinations. This is a tiny pill – smaller than Biktarvy – and let many people stop boosted PIs – or other complex combinations used by older people who have been on ART for more than 20 years.
• CROI 2026: Persistence and expansion of the HIV reservoir on long-term ART
  Short review of a plenary talk by John Mellors on the latest understanding about the HIV latent reservoir. Also highlights the RIO study.
• LEAP pre-CROI workshop 2026: recordings and presentations online
  Latest developments and approaches to long-acting and extended formulations from independent investigators and research companies at the important annual pre-CROI meeting.

• CROI 2026: Australian study of 4CMenB vaccine fails to protect gay men against gonorrhoea
  This new study is the second randomised clinical trial to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine. Many questions for why these results are so different to observational studies and generated a lot of discussions and questions.
• CROI 2026: Pritelivir active against drug resistant herpes in phase 3 study
  This phase 3 study showed that a new oral drug called pritelivir can work in people who have drug resistance to other herpes treatments. Available now in an expanded access programme while being reviewed by the FDA.
• CROI 2026: Continued HIV protection from 2:1:1 PrEP dosing in gay and bisexual men in Paris
  Long-term results from this 8-year French PrEP study in predominantly gay men continued to show efficacy of 2:1:1 dosing and the flexibility to switch to daily dosing and back depending on your circumstances.
• CROI 2026: US activist Peter Staley opens CROI: we must all be activists until the next US administration
  Analysis of the impact of last year’s US policies – and inspiring strategies for how to overcome them this year. The talk drew on the unique and dynamic history of ACT-UP to give us strength and hope for the future, when the current US administration will be replaced.
• CROI 2026: 11 mg dose selected for once-monthly MK-8527 for phase 3 PrEP studies
  The study looking as dose selection for this very exciting option for once-monthly oral PrEP.
• CROI 2026: Islatravir PrEP didn’t protect against M184V mutation in macaque study
  An interesting study by independent investigators looking at this now discontinued PrEP drug against HIV with drug resistance. Luckily, this is unlikely to affect the new replacement compound MK-8527.
• CROI 2026: Statement in support of science
  A statement by the conference organiser’s reflects the concerns of researchers to the current anti-science policies of the Trump administration. It is shocking that organises needed to do this but very important that they did.
• CROI 2026: Main themes and research to watch out for
  An early overview covering new HIV drugs, new PrEP drugs, bNAbs, HIV complications, GLP-1 weight-busting drugs in people with HIV, cure-related research, key populations,  the impact of US policy changes, new monitoring testa and more.

This page was ipdated on 24 April 2026 to include all reports from CROI 2026.